Advances in the intrinsic signaling pathway interactions and clinical translation of HR+/HER2+ breast cancer
Breast Cancer · 2025
DOI: 10.1007/s12282-025-01779-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Breast Cancer, 2025. Verfasst von Xinyu Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Rd., Wu…. Hauptthemen laut MEDLINE: Breast Neoplasms, Signal Transduction, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 156 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hormone receptor-positive (HR +) and HER2-positive (HER2+) breast cancers represent a biologically unique subset of breast malignancies characterized by the co-expression of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). These cancers exhibit distinct molecular features, often leading to aggressive growth and higher recurrence rates. HR+/HER2+ breast cancer cells can utilize estrogen and HER2-driven signaling pathways to promote proliferation, survival, and metastatic potential, presenting unique challenges and opportunities for treatment. The current therapeutic strategies focus on a combination of endocrine therapies, such as selective estrogen receptor modulators (e.g., tamoxifen) or aromatase inhibitors, with HER2-targeted therapies like trastuzumab, pertuzumab, or tyrosine kinase inhibitors, to concurrently inhibit both hormone and HER2-driven pathways. Despite initial treatment efficacy, resistance often develops through various mechanisms, including mutations in the PIK3CA gene, cross-talk between ER and HER2 signaling, and activation of alternative growth pathways. Ongoing research aims to improve patient outcomes by exploring novel combination therapies, including CDK4/6 inhibitors and PI3K/AKT/mTOR pathway inhibitors, and by targeting resistance pathways. This review highlights the molecular basis, treatment approaches, and emerging therapeutic strategies in HR+/HER2+ breast cancer, emphasizing the need for personalized and adaptive treatment strategies in managing this complex disease subtype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Rd., Wuhan, 430022, People's Republic of China.
- Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Rd., Wuhan, 430022, People's Republic of China. huangtaowh@163.com.
Zitieren
APA
Li, X., & Huang, T. (2025). Advances in the intrinsic signaling pathway interactions and clinical translation of HR+/HER2+ breast cancer. Breast Cancer. https://doi.org/10.1007/s12282-025-01779-3
Vancouver
Li X, Huang T. Advances in the intrinsic signaling pathway interactions and clinical translation of HR+/HER2+ breast cancer. Breast Cancer. 2025. doi:10.1007/s12282-025-01779-3
BibTeX
@article{Li2025,
author = {Li, Xinyu and Huang, Tao},
title = {Advances in the intrinsic signaling pathway interactions and clinical translation of HR+/HER2+ breast cancer},
journal = {Breast Cancer},
year = {2025},
doi = {10.1007/s12282-025-01779-3}
}
EUVIMED